Harmony Biosciences Holdings Inc Ordinary Shares HRMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HRMY is a good fit for your portfolio.
News
-
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
-
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
-
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
-
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
-
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
-
U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY
-
Harmony Biosciences Gets FDA Orphan Designation for Pitolisant in Prader-Willi Syndrome
-
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME
Trading Information
- Previous Close Price
- $29.23
- Day Range
- $28.14–28.98
- 52-Week Range
- $18.61–39.27
- Bid/Ask
- $28.01 / $28.94
- Market Cap
- $1.64 Bil
- Volume/Avg
- 313,047 / 384,732
Key Statistics
- Price/Earnings (Normalized)
- 9.38
- Price/Sales
- 3.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 6.10%
Company Profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 246
Comparables
Valuation
|
Metric
|
HRMY
|
CBAY
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.38 | — | — |
Price/Book Value | 3.57 | 12.65 | 2.99 |
Price/Sales | 3.04 | 111.01 | 1,857.18 |
Price/Cash Flow | 9.61 | — | — |
Price/Earnings
HRMY
CBAY
VRDN
Financial Strength
|
Metric
|
HRMY
|
CBAY
|
VRDN
|
|---|---|---|---|
Quick Ratio | 2.61 | 10.70 | 17.93 |
Current Ratio | 2.75 | 10.96 | 18.26 |
Interest Coverage | 7.68 | −5.27 | −137.76 |
Quick Ratio
HRMY
CBAY
VRDN
Profitability
|
Metric
|
HRMY
|
CBAY
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | 25.19% | −30.06% | −42.76% |
Return on Equity (Normalized) | 41.32% | −51.97% | −82.42% |
Return on Invested Capital (Normalized) | 30.06% | −30.87% | −50.70% |
Return on Assets
HRMY
CBAY
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lkvmpmndl | Bnms | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dfclmrbvc | Vgnhn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jdqxmpbl | Mkwzpl | $99.5 Bil | |
MRNA
| Moderna Inc | Qstchxmg | Fnhx | $38.8 Bil | |
ARGX
| argenx SE ADR | Hdmkylslg | Qyqz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Twsdcfmpf | Wxxtt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dkxcswnpg | Mnrrvf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xbgjczdw | Btvkbw | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tjlbmgytx | Cvnvdz | $12.5 Bil | |
INCY
| Incyte Corp | Cvnllxyr | Qflsfc | $11.6 Bil |